Facioscapulohumeral Muscular Dystrophy clinical trials at University of California Health

4 in progress, 2 open to eligible people

Showing trials for

  • AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

    open to eligible people ages 16-70

    A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)

    at UCLA UCSD

  • Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)

    open to all eligible people

    The primary goal of this proposal is to collect motor and functional outcomes specific to FSHD over time. By collecting measures specific to FSHD, this will help ensure the best level of clinical care is being provided. Also, the hope is to speed up drug development by gaining a better understanding of how having FSHD impacts motor function and other health outcomes (i.e. breathing, wheelchair use, etc.) and how big a change in motor function would be clinically meaningful to those with FSHD. Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD) will have approximately 450 FSHD participants followed for a minimum of 3 years. A subset of MOVE FSHD participants, approximately 200, will participate in the MOVE+ sub-study which includes whole body MRI and muscle biopsy.

    at UCLA

  • RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy

    Sorry, in progress, not accepting new patients

    The purpose of this study is to evaluate the pharmacodynamics, safety, tolerability, pharmacokinetics, and efficacy of RO7204239, a humanized monoclonal antibody that binds to human latent myostatin, in ambulant adult participants with facioscapulohumeral muscular dystrophy (FSHD).

    at UC Irvine

  • AOC 1020 in Adults With Facioscapulohumeral Muscular Dystrophy (FSHD)

    Sorry, accepting new patients by invitation only

    A Phase 2 Open-label Extension Study to Evaluate the Long-Term Safety, Tolerability, Efficacy, and Pharmacokinetics of AOC 1020 Administered Intravenously to Adult Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)

    at UCLA UCSD

Last updated: